Balding in men worsens with age.
January 2024 in “La Ciencia al Servicio de la Salud y Nutrición” Spironolactone is effective and safe for treating hair loss, excessive hair growth, and acne.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
75 citations
,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
1 citations
,
October 2019 in “Medicina UPB” Multiple treatment comparison meta-analyses help doctors make better decisions by comparing different interventions.
August 2023 in “Vittalle” Mais estudos são necessários para garantir a eficácia e qualidade dos tratamentos de alopecia com plantas medicinais.
Vaccination is crucial for public health, but anti-vaccine movements are a concern.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
August 2019 in “Journal of The American Academy of Dermatology” RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
June 1992 in “The Journal of dermatologic surgery and oncology” 7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
November 2025 in “International Journal of Innovative Research and Scientific Studies” Regenera Activa AMT effectively improves hair growth and reduces hair loss in androgenetic alopecia.
17 citations
,
November 2013 in “Clinical and experimental dermatology” Acitretin therapy may cause hair to repigment and curl.
16 citations
,
August 1989 in “PubMed” Retinol and L-cystine improve diffuse hair loss without side effects.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.